Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8909 results

  1. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]

    Awaiting development Reference number: GID-TA11874 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ectopic Pregnancy

    In development Reference number: GID-QS10202 Expected publication date:  06 May 2026

    Quality standard
    In development

  3. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

    Awaiting development Reference number: GID-TA11065 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]

    Awaiting development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]

    Awaiting development Reference number: GID-TA11877 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]

    Awaiting development Reference number: GID-TA11942 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Setrusumab for treating osteogenesis imperfecta [ID6730]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. CM-AT for behaviours associated with autism in children and young people [ID6731]

    Awaiting development Reference number: GID-TA11955 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  12. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

    Health technology evaluations
    In development

  14. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  15. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development